Highlights from the 43rd Annual J.P. Morgan Healthcare Conference
Home > About Us > News & Events > Highlights From the 43rd Annual J.P. Morgan Healthcare Conference
Highlights From the 43rd Annual J.P. Morgan Healthcare Conference
January 17, 2025
Now that the 43rd Annual J.P. Morgan Healthcare Conference ended yesterday, we’d like to congratulate LEAP clients Natera, NeoGenomics, Myriad Genetics, and Caris Life Sciences and the other presenters. We’d like to share a few of the presentations that really stood out for us. (You can find links to 360dx’s excellent coverage, some of which we’ve quoted, below.)
Exact Sciences
CEO Kevin Conroy said they’re “prepared to launch three new long-awaited cancer tests in 2025 in its ‘most productive year’ yet. The next-generation version of its Cologuard test Cologuard Plus is expected to launch early in the second quarter of 2025, while its molecular residual disease test Oncodetect is forecast for launch sometime in the second quarter. Its multi-cancer screening test Cancerguard will likely launch in the second half of 2025.”
Guardant Health
Co-CEO Helmy Eltoukhy said “the firm's 2024 year-over-year growth in clinical test volumes was largely driven by its Guardant360 test…The test was transitioned to Guardant's Smart Liquid Biopsy platform in July, which expanded the number of genes included and improved the test's sensitivity…The company has also seen ‘excellent uptake’ of the firm's Guardant360 TissueNext test thus far and has plans to launch the Guardant360 Tissue comprehensive genomic profiling test using the Smart platform technology this year…Guardant co-CEO AmirAli Talasaz noted that the firm is ramping up its commercial infrastructure for the Guardant Shield test, which received FDA clearance for colorectal cancer screening last year…and could have version 2 on the market this year.”
LabCorp
During a fireside chat, Chairman/CEO Adam Schechter addressed their “opposition to the US Food and Drug Administration's (FDA) regulation of laboratory-developed tests (LDTs) and its ongoing push for reform of the Protecting Access to Medicare Act (PAMA).” Also, on esoteric testing, “he said that LabCorp expects it will continue to see this segment of its business grow more quickly than its routine business. He highlighted oncology, neurology, autoimmune disease, and women's health as particularly fast growing areas.”
Grail
CEO Bob Ragusa discussed a new version of Galleri, the firm's blood-based multi-cancer early detection test. “Introduced in December, the new assay is ‘both fully automated and integrated,’ he said. Grail has eliminated ‘numerous’ manual steps, leading to greater efficiency and improved quality control. It has also reduced the methylation sequencing panel ‘to the most informative regions,’ allowing four times the number of samples to be run on a flow cell, leading to reduced sequencing costs. Grail has also updated the test report, revising how the cancer signal of origin is classified and simplifying the report to 18 regions.”
What were your highlights? Tell us below. If you’d like some context for it all, contact us and let’s talk!
Links to Coverage in 360dx: